Coherus BioSciences, Inc. Q3 2026 Earnings Recap

Coherus shares fell 21.6% after earnings, as investors appear to have focused on the company’s need to sharply reduce costs and its reliance on growing LOQTORZI revenue to cover core cash burn. Management plans a 30% headcount reduction and narrowed tagmokitug development to esophageal cancer, but the transcript does not provide evidence that LOQTORZI has yet reached the revenue level needed to support the business.

Key Takeaways

• Coherus expects rightsizing and other cost reductions to save $6 million–$7 million per quarter, lowering the LOQTORZI revenue needed to cover core cash burn from $30 million–$35 million to $25 million–$30 million per quarter.
• The company plans to cut headcount by 30% and focus tagmokitug development on first- and second-line esophageal cancer, after exploring multiple cancer types and more than 120 patients.
• Management cited interim tagmokitug data in combination with toripalimab as support for seeking ex-U.S. partners; it is engaging a financial adviser to conduct the partnering process.
• LOQTORZI’s share of the nasopharyngeal cancer market is about 20%–22%, while roughly 30% of patients still receive chemotherapy alone, which management sees as a growth opportunity.
• Management said the U.S. manufacturing process transfer for toripalimab was completed in Q3 2026; the FDA action date for the drug-product portion of the application is November 30.